Claims for Patent: 11,413,351

Summary for Patent: 11,413,351

Title:	CNP prodrugs with carrier attachment at the ring moiety
Abstract:	The present invention relates to CNP prodrugs in which the carrier is covalently and reversibly attached to the ring moiety of a CNP moiety, to pharmaceutical compositions comprising such CNP prodrugs, to their uses and to methods of treating diseases that can be treated with the CNP prodrugs of the present invention.
Inventor(s):	Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen
Assignee:	Ascendis Pharma Endocrinology Division AS
Application Number:	US16/067,095
Patent Claims:	1. A C-type natriuretic peptide (CNP) prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety —D comprising a ring moiety, wherein the ring moiety has the amino acid sequence of SEQ ID NO:96, provided the methionine at position 11 of SEQ ID NO:96 can be substituted with asparagine, the ring moiety being between two cysteine residues forming a disulfide bridge; and a non-toxic carrier moiety —Z that is conjugated through a moiety —L2— to a reversible prodrug linker moiety —L1—, which reversible prodrug linker moiety —L1— is covalently and reversibly conjugated to a side chain of an amino acid residue of said ring moiety of —D or to the backbone of said ring moiety of —D; and wherein —L2— is a chemical bond or a spacer. 2. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein —L1— is covalently and reversibly conjugated to the side chain of an amino acid residue of the ring moiety of —D. 3. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein —L1— is conjugated to the ring moiety of —D through a functional group of a corresponding CNP drug D-H selected from the group consisting of carboxylic acid, primary amine, hydroxyl, disulfide and guanidine. 4. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein —L1— is connected to the ring moiety of —D through a linkage selected from the group consisting of amide, ester, carbamate, acetal, aminal, imine, oxime, hydrazone, disulfide and acylguanidine. 5. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein the amino acid residue of the ring moiety of —D to which —L1— is conjugated is selected from the group consisting of lysine, serine, aspartic acid and arginine. 6. The CNP prodrug or pharmaceutically acceptable salt thereof of claim 1, wherein the amino acid residue of the ring moiety of —D to which —L1— is conjugated is lysine. 7. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein —D has the sequence of SEQ ID NO:24. 8. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein —D has the sequence of SEQ ID NO:24 and —L1— is conjugated to the lysine at position 26. 9. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein —L1— is of formula (II): wherein the dashed line indicates attachment to a nitrogen of an amino acid side chain of the ring moiety of the CNP moiety by forming an amide bond; —X— is —C(R4R4a)—; —N(R4)—; —O—; —C(R4R4a)—C(R5R5a)—; —C(R5R5a)—C(R4R4a)—; —C(R4R4a)—N(R6)—; —N(R6)—C(R4R4a)—; —C(R4R4a)—O—; —O—C(R4R4a)—; or —C(R7R7a)—; X1 is C; or S(O); —X2— is —C(R8R8a)—; or —C(R8R8a)—C(R9R9a)—; ═X3 is ═O; ═S; or ═N—CN; —R1, —R1a, —R2, —R2a, —R4, —R4a, —R5, —R5a, —R6, —R8, —R8a, —R9, —R9a are independently selected from the group consisting of —H; and C1-6 alkyl; —R3, —R3a are independently selected from the group consisting of —H; and C1-6 alkyl, provided that in case one of —R3, —R3a or both are other than —H they are connected to N to which they are attached through an sp3-hybridized carbon atom; —R7 is —N(R10R10a); or —NR10—(C═O)—R11; —R7a, —R10, —R10a, —R11 are independently of each other —H; or C1-6 alkyl; optionally, one or more of the pairs —R1a/—R4a, —R1a/—R5a, —R1a/—R7a, —R4a/—R5a, —R8a/—R9a form a chemical bond; optionally, one or more of the pairs —R1/—R1a, —R2/—R2a, —R4/—R4a, —R5/—R5a, —R8/—R8a, —R9/—R9a are joined together with the atom to which they are attached to form a C3-10 cycloalkyl; or 3- to 10-membered heterocyclyl; optionally, one or more of the pairs —R1/—R4, —R1/—R5, —R1/—R6, —R1/—R7a, —R4/—R5, —R4/—R6, —R8/—R9, —R2/—R3 are joined together with the atoms to which they are attached to form a ring A; optionally, R3/R3a are joined together with the nitrogen atom to which they are attached to form a 3- to 10-membered heterocycle; A is selected from the group consisting of phenyl; naphthyl; indenyl; indanyl; tetralinyl; C3-10 cycloalkyl; 3- to 10-membered heterocyclyl; and 8- to 11-membered heterobicyclyl; and wherein —L1— is substituted with —L2—Z and wherein —L1— is optionally further substituted, provided that the hydrogen marked with the asterisk in formula (II) is not replaced by —L2—Z or a substituent. 10. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein —L2— is selected from the group consisting of -T-, —C(O)O—, —O—, —C(O)—, —C(O)N(Ry1)—, —S(O)2N(Ry1)—, —S(O)N(Ry1)—, —S(O)2—, —S(O)—, —N(Ry1)S(O)2N(Ry1a)—, —S—, —N(Ry1)—, —OC(ORy1)(Ry1a)—, —N(Ry1)C(O)N(Ry1a)—, —OC(O)N(Ry1)—, C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl; wherein -T-, C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally substituted with one or more —R2, which are the same or different and wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, —C(O)O—, —O—, —C(O)—, —C(O)N(Ry3)—, —S(O)2N(Ry3)—, —S(O)N(Ry3)—, —S(O)2—, —S(O)—, —N(Ry3)S(O)2N(Ry3a)—, —S—, —N(Ry3)—, —OC(ORy3)(Ry3a)—, —N(Ry3)C(O)N(Ry3a)—, and —OC(O)N(Ry3)—; —Ry1 and —Ry1a are independently of each other selected from the group consisting of —H, -T, C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl; wherein -T, C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally substituted with one or more —Ry2, which are the same or different, and wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, —C(O)O—, —O—, —C(O)—, —C(O)N(Ry4)—, —S(O)2N(Ry4)—, —S(O)N(Ry4)—, —S(O)2—, —S(O)—, —N(Ry4)S(O)2N(Ry4a)—, —S—, —N(Ry4)—, —OC(ORy4)(Ry4a)—, —N(Ry4)C(O)N(Ry4a)—, and —OC(O)N(Ry4a)—; each T is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8- to 30-membered carbopolycyclyl, and 8- to 30-membered heteropolycyclyl; wherein each T is independently optionally substituted with one or more —Ry2, which are the same or different; each —Ry2 is independently selected from the group consisting of halogen, —CN, oxo (═O), —COORy5, —ORy5, —C(O)Ry5, —C(O)N(Ry5Ry5a), —S(O)2N(Ry5Ry5a), —S(O)N(Ry5Ry5a), —S(O)2Ry5, —S(O)Ry5, —N(Ry5)S(O)2N(Ry5aRy5b), —SRy5, —N(Ry5Ry5a), —NO2, —OC(O)Ry5, —N(Ry5)C(O)Ry5a, —N(Ry5)S(O)2Ry5a, —N(Ry5)S(O)Ry5a, —N(Ry5)C(O)ORy5a, —N(Ry5)C(O)N(Ry5aRy5b), —OC(O)N(Ry5Ry5a), and C1-6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different; and each —Ry3, —Ry3a, —Ry4, Ry4a, —Ry5, —Ry5a and —Ry5b is independently selected from the group consisting of —H, and C1-6 alkyl, wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different. 11. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein —Z comprises a branched polymer. 12. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 11, wherein the branched moiety —Z has a molecular weight of 10 kDa to 80 kDa. 13. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein —Z comprises a moiety of formula (a) wherein the dashed line indicates attachment to —L2— or to the remainder of —Z; BPa is a branching point selected from the group consisting of —N<, —CR< and >C<; —R is selected from the group consisting of —H and C1-6 alkyl; a is 0 if BPa is —N< or —CR< and a is 1 if BPa is >C<; —Sa—, —Sa′—, —Sa″— and —Sa′″— are independently of each other a chemical bond or are selected from the group consisting of C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl; wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally substituted with one or more —R1, which are the same or different and wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, —C(O)O—, —O—, —C(O)—, —C(O)N(R2)—, —S(O)2N(R2)—, —S(O)N(R2)—, —S(O)2—, —S(O)—, —N(R2)S(O)2N(R2a)—, —S—, —N(R2)—, —OC(OR2)(R2a)—, —N(R2)C(O)N(R2a)—, and —OC(O)N(R2)—; each -T- is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8- to 30-membered carbopolycyclyl, and 8- to 30-membered heteropolycyclyl; wherein each -T- is independently optionally substituted with one or more —R1, which are the same or different; each —R1 is independently selected from the group consisting of halogen, —CN, oxo(═O), —COOR3, —OR3, —C(O)R3, —C(O)N(R3R3a), —S(O)2N(R3R3a), —S(O)N(R3R3a), —S(O)2R3, —S(O)R3, —N(R3)S(O)2N(R3aR3b), —SR3, —N(R3R3a), —NO2, —OC(O)R3, —N(R3)C(O)R3a, —N(R3)S(O)2R3a, —N(R3)S(O)R3a, —N(R3)C(O)OR3a, —N(R3)C(O)N(R3aR3b), —OC(O)N(R3R3a), and C1-6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different; each —R2, —R2a, —R3, —R3a and —R3b is independently selected from the group consisting of —H, and C1-6 alkyl, wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different; and —Pa′, —Pa″ and —Pa′″ are independently a polymeric moiety. 14. A pharmaceutical composition comprising at least one CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1 and at least one excipient. 15. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein —Z comprises a fatty acid derivative. 16. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein —Z is a fatty acid derivative. 17. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein —L1— is of formula (V): wherein the dashed line indicates attachment to an amine functional group of a side chain of an amino acid residue of the ring moiety of the CNP moiety; —R1 is selected from the group consisting of optionally substituted C1—C6 linear, branched, or cyclic alkyl; optionally substituted aryl; optionally substituted heteroaryl; alkoxy; and —NR5 2; —R2 is selected from the group consisting of —H; optionally substituted C1—C6 alkyl; optionally substituted aryl; and optionally substituted heteroaryl; —R3 is selected from the group consisting of —H; optionally substituted C1—C6 alkyl; optionally substituted aryl; and optionally substituted heteroaryl; —R4 is selected from the group consisting of —H; optionally substituted C1—C6 alkyl; optionally substituted aryl; and optionally substituted heteroaryl; and each —R5 is independently of each other selected from the group consisting of —H; optionally substituted C1—C6 alkyl; optionally substituted aryl; and optionally substituted heteroaryl; or when taken together two —R5 can be cycloalkyl or cycloheteroalkyl.